Core A: Administrative Core

项目概要/摘要-行政核心（核心A） 行政核心将提供科学和行政领导，远见，方向，协调， 整合、管理、监督、资源共享和协作任务、支助和问责制 亚利桑那州阿尔茨海默病研究中心（ADRC）它还将提供科学的领导， 来自亚利桑那州阿尔茨海默氏症12个参与组织的150多名研究人员的中心 联合会（AAC），使其有可能大大增加和优化我们的共享资源的利用率。 资源，支持广泛的研究人员研究，开发新的研究和临床计划， 下一代AD和相关痴呆（ADRD）研究人员，并进一步发展我们的全州模型， 在AD研究方面的合作。它将允许我们的ADRC核心，组织支持的附属大脑， 身体捐赠计划（BBDP），附属APOE计划，以及待定的NIA赠款支持的APOE 4/APOE 2 等位基因剂量队列提供NACC和NCRAD年度共享数据和样本的共享资源， 每年约有1，650名研究参与者，其中包括每年约100名捐赠大脑的参与者 并在他们死后进行全面的神经病理学评估，并支持我们的总体主题： “血液生物标志物（BBB）在AD的诊断，临床前研究和预防中的应用。它将利用 与我们的核心，REC，附属计划，研究人员，临床医生和 组织和国家领导人，密切的工作关系和成功的良好记录，共享 致力于预防AD，以及拟议的ADRC的存在，以帮助确保和利用 主要的国家，组织和慈善投资，最大限度地发挥ADRC的影响，实现其雄心勃勃的， 积极合作的目标，并继续使打击ADRD在亚利桑那州的首要任务。它将 与NIA，NACC，NCRAD，其他ADRC和研究计划密切合作，以及广泛的其他 组织和利益相关者团体，与两个少数民族老龄化研究资源中心合作 （RCMARs），我们的核心和REC，以帮助开发ADRD相关的美洲原住民和西班牙裔/拉丁裔 研究人员、研究参与者登记和研究。它将管理ADRC的计划， 征集、竞争性评估和支持四个国家情报局赞助的24个月发展项目， 在资助期间，国家支持了10个为期12个月的试点项目。它将利用ADRC，盖茨 风险投资和组织资金，以帮助建立NACC和NCRAD共享数据的宝贵资源 和生物样本，用于验证脑捐赠计划参与者中出现的BBB， 代表性不足的少数群体，并支持他们在AD研究药物中的潜在转型作用 开发，研究和临床护理，增加我们的研究人员，同事和 合作者寻找并支持2025年AD预防治疗的可用性和可负担性，并帮助 实现国家阿尔茨海默病项目法案（NAPA）的目标。

PROJECT SUMMARY/ABSTRACT - ADMINISTRATIVE CORE (CORE A) The Administrative Core will provide scientific and administrative leadership, vision, direction, coordination, integration, management, oversight, resource-sharing and collaborative mandates, support, and accountability for the Arizona Alzheimer's Disease Research Center (ADRC). It will also provide the scientific leadership and hub for more than 150 researchers from twelve participating organizations in the Arizona Alzheimer's Consortium (AAC), making it possible to dramatically augment and optimize the utilization of our shared resources, support a wide range of researcher studies, develop new research and clinical programs and the next generation of AD and related dementia (ADRD) researchers, and further develop our statewide model of collaboration in AD research. It will permit our ADRC Cores, organizationally supported Affiliated Brain and Body Donation Program (BBDP), Affiliated APOE Program, and pending NIA grant-supported APOE4/APOE2 Allelic Dose Cohort to provide a shared resource of annual NACC- and NCRAD-shared data and samples from about 1,650 research participants per year, including about 100 participants per year who donate their brains and have comprehensive neuropathological assessments after they die, and support our overarching theme: “blood-based biomarkers (BBBs) in the diagnosis, preclinical study and prevention of AD.” It will capitalize on longstanding relationships with our Cores, REC, Affiliated Programs, researchers, clinicians, and organizational and state leaders, a strong record of close working relationships and success, a shared commitment to the prevention of AD, and the proposed ADRC's very existence to help secure and leverage major state, organization and philanthropic investments, maximize the ADRC's impact, fulfill its ambitious and aggressively collaborative goals, and continue to make the fight against ADRD a top priority in Arizona. It will work closely with NIA, NACC, NCRAD, other ADRCs and research programs, and a wide range of other organizations and stakeholder groups, partner with two Resource Centers for Minority Aging Research (RCMARs), our Cores and REC to help develop ADRD-related Native American and Hispanic/Latino researchers, research participant enrollment, and studies. It will administer the ADRC's program for the solicitation, competitive evaluation, and support of four NIA-sponsored 24-month Developmental Projects and ten state-supported 12-month Pilot Projects during the funding period. It will capitalize on ADRC, Gates Ventures and organizational funds to help establish an invaluable resource of NACC and NCRAD-shared data and biological samples for the validation of emerging BBBs in brain donation program participants and underrepresented minority groups and support their potentially transformational roles in AD research drug development, research and clinical care, increase the opportunity for our researchers, colleagues and collaborators to find and support the availability and affordability of an AD prevention therapy in 2025, and help fulfill the goals of the National Alzheimer's Project Act (NAPA).